

24 February 2021

Daniel Ireland
d Ireland@ccz.com.au
+61 2 9238 8239

Laserbond Limited (LBL)

Stronger second half expected, Products division performing well

Recommendation: BUY

Target Price: 83cps (previous 108cps)

Market Capitalization: \$54m

Index: None

Share Price: 56cps

Sector: Industrials

Values in AUD'm unless otherwise stated

YE Jun	2019A	2020A	2021E	2022E	2023E
Revenue	22.7	22.2	27.0	32.3	37.6
EBITDA	4.9	6.2	7.3	8.1	9.5
U-NPAT	2.8	2.8	3.3	3.8	4.7
U-EPS (cps)	3.0	3.0	3.5	4.0	4.9
U-EPS growth	193.8%	1.7%	15.3%	14.1%	24.0%
U/PE	19.0x	18.7x	16.2x	14.2x	11.4x
EV/EBIT	17.8x	17.4x	15.6x	13.7x	10.6x
Div Yield	1.8%	2.0%	2.1%	2.5%	2.9%



Report HY	2H-20	1H-21	2H-21	1H-22
U-NPAT	1.7	1.2	2.3	1.8
Div (cps)	0.6	0.6	0.7	0.7

- First half update:** LBL declared 1H21 revenue and EBITDA of \$11.8 M and \$3.1M respectively (vs \$11.3M and \$2.7M pcp up +4.8% and +13.4%). The result was lower than expectations, largely due to COVID-19 restrictions causing delays in interstate transportation of parts to LBL's facilities in NSW, SA and Victoria. Most notably, LBL's softer services revenue that experienced delayed sales from new customers and reduced maintenance servicing for large mining and manufacturing businesses. However, the company is expecting a stronger second-half contribution from the services division (46% of group revenues 1H21) with the company declaring a 'record volume of open quotes for active opportunities that currently exceeds \$10M, with much of this work expected to proceed'.
- Services softer, Product sales strong:** LBL displayed strong product sales during the first half (\$6.3M up from \$4.36M, +45% vs pcp), due to a product reconfiguration from a material OEM customer, combined with strong general demand. Management also highlighted several new products will add to the current sales momentum, including NanoClad® and EClad® which are close to commercialisation and promise to disrupt significant addressable markets. With lockdowns interrupting business conditions in 1H21, United Surfacing Technologies (UST), which was acquired in June 20, is expected to rebound in the second half, regaining the lost momentum caused by lockdowns in Victoria.
- Technology Division:** LBL have 'two promising local opportunities and one international opportunity under negotiation', and we expect more opportunities will open as border restrictions ease. This will enable LBL's sales force to meet customers face to face, further increasing tech sales and licensing revenues. The company noted that a technology sale in the US was imminent, subject to final testing, however we have not included these in our numbers given the uncertainty in timing (tech sales have traditionally added between \$1.2M-\$1.7M revenue for a core laser cladding cell, \$200K in licensing revenue and \$1M in consumables pa).
- Valuation:** We reduced our valuation to \$0.83 per share (previously \$1.08) taking into account a weaker services contribution. We have reduced our estimates for FY21 Revenue to \$27M and NPAT to \$3.3M (CCZ prior forecast Rev \$32.3M and NPAT \$4.2M) excluding technology sales in the second half in our assumptions. We have also reduced the company's Fy22 \$40M revenue target and only included organic revenue growth as it remains unclear as to the timing of an acquisition which is required to reach the company's stated target.

CCZ EQUITIES PTY LIMITED
LEVEL 24, 9 CASTLEREAGH STREET, SYDNEY NSW 2000, GPO BOX 5045, SYDNEY NSW 2001 T: 61 2 9238 8238 E: CCZ@CCZ.COM.AU

LASERBOND (LBL.AX)

Market Capitalization	54m	Index Sector	None Industrials	Year End Shares on Issue (m)	Jun 95.7
Share Price (AUD/share)	0.56				
Recommendation	BUY	LBL.AX Investment Thesis	Services revenue declined for the half, however the Products division was up 45% on pcp. LBL is expecting a stronger 2nd half as orders regain momentum post COVID-19 lockdowns.		
Target Price (AUD/share)	0.83				
Total Shareholder Return	+50.2%				

Returns Analysis	2019A	2020A	2021	2022	2023	Balance Sheet	2019A	2020A	2021	2022	2023
Underlying EPS (AUD cps)	2.95	3.00	3.46	3.95	4.90	Cash & Equivalents	2.2	4.0	2.7	4.5	9.5
Growth	193.8%	1.7%	15.3%	14.1%	24.0%	Trade Receivables	5.4	4.4	5.9	7.1	8.2
Wtd Avg SOI	94.5	94.5	95.7	95.7	95.7	Inventories	2.5	3.5	4.1	4.4	5.1
PE	19.0x	18.7x	16.2x	14.2x	11.4x	Other	0.0	0.0	0.0	0.0	0.0
PEG	13.1x	10.8x	1.1x	1.0x	0.5x	Total Current Assets	10.1	11.8	12.7	15.9	22.8
EV/EBITDA	14.5x	11.8x	10.5x	9.2x	7.4x	PPE	5.9	11.4	13.7	14.4	15.1
EV/EBIT	17.8x	17.4x	15.6x	13.7x	10.6x	Goodwill	0.0	0.0	0.6	0.6	0.6
Dividend	1.00	1.10	1.20	1.40	1.60	Intangibles	0.0	0.0	0.0	0.0	0.0
Div Yield	1.8%	2.0%	2.1%	2.5%	2.9%	Other	0.4	0.4	0.5	0.6	0.8
Franking	100.0%	100.0%	100.0%	100.0%	100.0%	Total Non-Current Assets	6.3	11.8	14.8	15.6	16.4
Payout Ratio	33.9%	36.7%	34.7%	35.4%	32.7%	Total Assets	16.4	23.6	27.5	31.5	39.2
ROFE	39.7%	34.6%	33.8%	32.4%	28.8%	Trade Payables	2.0	1.3	2.3	2.8	3.2
ROE	27.7%	23.2%	23.0%	22.4%	20.3%	Debt	2.9	8.5	8.9	9.6	10.6
ROA	17.0%	12.0%	12.1%	12.0%	12.0%	Provisions	0.7	0.7	0.7	0.7	0.8
Gearing (ND/ND+E)	(28%)	(49%)	(23%)	(36%)	(70%)	Other	0.8	0.9	1.2	1.6	1.6
ND/EBITDA	(0.4x)	(0.6x)	(0.4x)	(0.6x)	(1.0x)	Total Liabilities	6.3	11.4	13.1	14.7	16.1
EBITDA Interest Cover	27.6x	14.1x	16.2x	20.3x	23.8x	Net Assets	10.1	12.2	14.4	16.8	23.1
Cash Conversion	106%	91%	87%	92%	88%	Contributed Equity	6.7	7.0	7.0	7.0	7.0
Free Cash Yield	2.6%	4.6%	(1.0%)	4.4%	4.9%	Retained Earnings	3.3	5.2	7.4	9.8	16.1

Income Statement	2019A	2020A	2021	2022	2023	Cash Flow Statement	2019A	2020A	2021	2022	2023
<u>Underlying</u>						Cash Received	25.5	26.9			
Revenue	22.7	22.2	27.0	32.3	37.6	Cash Paid	(20.3)	(21.2)			
Underlying EBITDA	4.9	6.2	7.3	8.1	9.5	Cash EBITDA			7.3	8.1	9.5
D&A	(0.9)	(2.0)	(2.4)	(2.7)	(2.9)	Working Capital Change			(0.9)	(0.7)	(1.2)
Underlying EBIT	4.0	4.2	4.9	5.4	6.7	Net Interest Paid	(0.2)	(0.4)	(0.5)	(0.4)	(0.4)
Net Interest	(0.2)	(0.4)	(0.5)	(0.4)	(0.4)	Tax Paid	(0.9)	(1.0)	(1.1)	(1.3)	(1.6)
Underlying PBT	3.8	3.8	4.4	5.0	6.3	Other			0.0	0.0	0.0
Tax	(1.0)	(1.0)	(1.1)	(1.3)	(1.6)	Operating Cash Flow	4.1	4.3	4.8	5.8	6.4
Underlying NPAT	2.8	2.8	3.3	3.8	4.7	Capital Expenditure	(3.4)	(0.6)	(3.3)	(2.4)	(2.8)
<u>Statutory</u>						Net Acquisitions	0.0	0.0	(1.1)	0.0	0.0
Underlying PBT	3.8	3.8	4.4	5.0	6.3	Other	0.0	0.0	0.0	0.0	0.0
One-offs	0.0	0.0	0.0	0.0	0.0	Investing Cash Flow	(3.4)	(0.6)	(4.4)	(2.4)	(2.8)
PBT	3.8	3.8	4.4	5.0	6.3	Change in Debt	0.0	0.0	0.4	0.7	0.8
Tax	(1.0)	(1.0)	(1.1)	(1.3)	(1.6)	Change in Equity	0.0	0.0	0.0	0.0	0.0
NPAT	2.8	2.8	3.3	3.8	4.7	Dividends Paid	(0.5)	(0.6)	(1.2)	(1.3)	1.5
Basic EPS (AUD cps)	2.95	3.00	3.46	3.95	4.90	Other	0.7	(1.2)	(1.0)	(1.0)	(1.0)
Sales Growth	44.9%	(2.2%)	21.7%	19.4%	16.7%	Financing Cash Flow	0.2	(1.9)	(1.7)	(1.6)	1.4
Underlying NPAT Growth	195.9%	1.7%	16.8%	14.1%	24.0%	Starting Cash	1.4	2.2	4.0	2.7	4.5
Basic EPS Growth	195.9%	1.7%	16.8%	14.1%	24.0%	Net Cash Flow	0.8	1.8	(1.3)	1.8	5.0
EBITDA Margin	21.5%	28.0%	26.9%	25.2%	25.3%	Ending Cash	2.2	4.0	2.7	4.5	9.5
EBIT Margin	17.6%	19.1%	18.0%	16.9%	17.7%	Free Cash Flow	1.4	2.4	(0.5)	2.4	2.6
Underlying NPAT Margin	12.3%	12.8%	12.3%	11.7%	12.5%						

Interim Expectations	1H-20A	2H-20A	1H-21E	2H-21E	1H-22E	Valuation	2021E	2022E	2023E	2024E	2025E
Revenue	11.3	10.9	11.8	15.2	15.0	NPV of FCF & TV	78.1	88.4	99.8	112.0	124.9
EBITDA	2.7	3.5	3.1	4.2	3.8	Number of Shares	95.7	95.7	95.7	95.7	95.7
EBIT	1.8	2.4	1.9	2.9	2.7	DCF Valuation per Share	0.83	0.94	1.06	1.19	1.32
Underlying NPAT	1.2	1.7	1.2	2.1	1.8						
NPAT	1.2	1.7	1.2	2.1	1.8	Substantial Shareholders					
Basic EPS (AUD cps)	1.22	1.78	1.24	2.22	2.70	Ms Diane Constance Hooper		10.2%			
Dividend (AUD cps)	0.50	0.60	0.60	0.70	0.70	Mr Wayne Edward Hooper		10.2%			
Gearing	(30.9%)	(48.5%)	(36.7%)	(23.1%)	(32.1%)	Mr Rex John Hooper		7.6%			
Cash Conversion	20.9%	106.2%	79.7%	77.1%	97.4%	Ms Lillian Hooper		6.5%			
Sales Growth	7.3%	9.4%	4.8%	41.5%	27.1%						
EBIT Margin	15.9%	22.4%	16.3%	19.4%	17.7%						

ASX DISCLAIMER

This report was prepared solely by CCZ Equities Pty Ltd (ABN 16 104 843 370). ASX Limited ABN 98 009 642 691 and its related bodies corporate ("ASX") did not prepare any part of the report and has not contributed in any way to its content. The role of ASX in relation to the preparation of the research reports is limited to funding their preparation, by CCZ Equities Pty Ltd, in accordance with the ASX Equity Research Scheme.

ASX does not provide financial product advice. The views expressed in this research report may not necessarily reflect the views of ASX. To the maximum extent permitted by law, no representation, warranty or undertaking, express or implied, is made and no responsibility or liability is accepted by ASX as to the adequacy, accuracy, completeness or reasonableness of the research reports.

Disclosures

Shareholding in Reported Stock(s)	Personal Holdings	Family Holdings	Investment Banking	Other Conflicts
Publishing Analyst	Yes/No	Yes/No		
Head of Research	Yes/No	Yes/No		
Company: CCZ Equities	Yes/No		Yes/No	Yes/No

Personal or Family Holdings: Where there may be a personal or family holding by the Publishing Analyst, it is at or below 0.1% of quoted shares on issue.
Investment Banking: No conflict of interest to disclose.
Other Conflicts: No conflict of interest to disclose.

Disclaimers

Type	Description
Publishing Analyst Daniel Ireland	The views and opinions expressed in this report are those of the research analyst and have not been influenced by the corporate advisory team, the subject company(s) or their other advisors. To the best of his/her knowledge, the Research Analyst is not in receipt of inside information and the research does not contain inside information.
Head of Research Raju Ahmed	The views and opinions expressed in this report are those of the research analyst and have not been influenced by the corporate advisory team, the subject company(s) or their other advisors.
General Disclaimer	This is a research publication of CCZ Equities Pty Limited ('CCZ Equities') ABN 97 085 277 881 as a Corporate Authorised Representative reference number 273728 of CCZ Statton Equities Pty Ltd ABN 16 104 843 370 AFS Licence 239946 ("CCZ Statton Equities") and is issued on the basis that it is only for the information of the particular person(s) or organisation(s) to whom it is provided. This document is being distributed to wholesale clients as defined in section 761G(7) of the Corporations Act 2001. This research publication may not be reproduced, redistributed or published by any recipient for any purpose unless otherwise agreed in writing by CCZ Equities beforehand. Any recommendations contained herein are unsolicited general information only. Recommendations are based on consideration of the securities alone, and as such are conditional and must not be relied upon without specific advice from your securities adviser as to their appropriateness to you given your individual investment objectives, financial situation and particular needs. Under no circumstances is this research publication to be used or considered as an offer to sell, or a solicitation of an offer to buy. The information herein has been obtained from, and any opinions herein are based upon, sources believed reliable, but CCZ Equities makes no representation as to its accuracy or completeness and should not be relied upon as such. All opinions and estimates herein reflect the judgement of CCZ Equities on the date of this research publication and are subject to change without notice. CCZ Equities, its related companies, employees, representatives and agents expressly advise that they shall not be liable in any way whatsoever for any loss or damage, whether direct, indirect, consequential or otherwise howsoever arising (whether in negligence or otherwise) out of or in connection with the contents of and/or any omissions from this communication except where a liability is made non-excludable by legislation. From time to time CCZ Equities, its related companies, or their associates and employees may have an interest in securities directly or indirectly the subject of this research publication or may perform services for, or solicit business from, a company the subject of this research publication and may receive fees, commissions or other compensation in such capacities.

Contacts List

Institutional Research	Institutional Sales & Dealing	Statton Securities (Retail)
Daniel Ireland Industrials +61 2 9238 8239	Adrian Scott Charles Caskey David Dahdah David Hofman Ian Cameron John Peisley John Zemek Scott Hildebrand +61 2 9238 8231 +61 2 9238 8230 +61 2 9238 8258 +61 2 9238 8225 +61 2 9238 8224 +61 2 9238 8227 +61 2 9238 8226 +61 2 9238 8233	Brian Chung Dyan Comino Eric Cheung Geoff Travers Harry Benetto Stuart Gray Stuart Hudson Todd Payne +61 2 9232 8241 +61 2 9232 8247 +61 2 9232 8246 +61 2 9232 8242 +61 2 9232 8243 +61 2 9232 8248 +61 2 9232 8245 +61 2 9232 8244
Louis Bannon Industrials +61 2 9238 8236		
Raju Ahmed Building Materials, Waste Management, General Industrials +61 2 9238 8237		
	Corporate Finance	Administration
	Ian Cameron +61 2 9238 8224	Jo-Anne Elliott +61 2 9238 8223

Office Address: Level 24, 9 Castlereagh Street, Sydney, NSW 2000, Australia.